Biotech giant CSL has reported a 17% increase in full-year statutory profit to US$3 billion ($4.6 billion) and announced ...

Investors, spooked by CSL's FY25 results, a surprise restructuring, job cuts, and strategic demerger, sold off the stock and sent the share price crashing nearly 17% by the end of the day. It was the ...

CSL Limited announced a significant transformation initiative aimed at enhancing its operational efficiency and shareholder value. The company reported a 17% increase in net profit after tax for the ...

The decision to demerge the CSL Seqirus business into a separate ASX-listed company will allow it to "set an independent ...

With CSL Ltd (ASX: CSL) shares now down 21% since Monday, the ASX 200 biotech giant looks like a screaming bargain. Here’s ...

In a significant move, CSL has announced plans to cut nearly 3,000 jobs and spin off its vaccines unit as part of a major corporate restructuring. This decision comes as the company navigates the ...

CSL faces an uphill battle to convince investors that its biggest restructure in decades will insulate the global healthcare ...

CSL’s $20 billion wipeout after a shock restructure announcement dragged the ASX lower, as investors punished the biotech ...

Biotech giant CSL saw its share price tank on Tuesday, which dragged the ASX down. Look back on the day's events and insights ...

Two of Australia’s corporate heavyweights, CSL (ASX: CSL) and BHP Group (ASX: BHP), released their earnings results today – ...